MDXG Valuation

MiMedx Group Inc

Add to Watchlist

Advanced Chart

7.100

-0.08(-1.114%)1D

Overview
Forecast
Valuation
Earnings

MDXG Relative Valuation

MDXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDXG is overvalued; if below, it's undervalued.

Historical Valuation

MiMedx Group Inc (MDXG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.64 is considered Undervalued compared with the five-year average of 4.83. The fair price of MiMedx Group Inc (MDXG) is between 32.84 to 37.46 according to relative valuation methord. Compared to the current price of 7.10 USD , MiMedx Group Inc is Undervalued By 78.38%.

Relative Value

Fair Zone

32.84-37.46

Current Price：7.10

78.38%

Undervalued

25.64

Trailing

Forward

11.50

EV/EBITDA

MiMedx Group Inc. (MDXG) has a current EV/EBITDA of 11.50. The 5-year average EV/EBITDA is 9.19. The thresholds are as follows: Strongly Undervalued below -63.33, Undervalued between -63.33 and -27.07, Fairly Valued between 45.46 and -27.07, Overvalued between 45.46 and 81.72, and Strongly Overvalued above 81.72. The current Forward EV/EBITDA of 11.50 falls within the Historic Trend Line -Fairly Valued range.

17.16

EV/EBIT

MiMedx Group Inc. (MDXG) has a current EV/EBIT of 17.16. The 5-year average EV/EBIT is -12.60. The thresholds are as follows: Strongly Undervalued below -91.02, Undervalued between -91.02 and -51.81, Fairly Valued between 26.61 and -51.81, Overvalued between 26.61 and 65.81, and Strongly Overvalued above 65.81. The current Forward EV/EBIT of 17.16 falls within the Historic Trend Line -Fairly Valued range.

2.64

MiMedx Group Inc. (MDXG) has a current PS of 2.64. The 5-year average PS is 2.74. The thresholds are as follows: Strongly Undervalued below 0.60, Undervalued between 0.60 and 1.67, Fairly Valued between 3.81 and 1.67, Overvalued between 3.81 and 4.88, and Strongly Overvalued above 4.88. The current Forward PS of 2.64 falls within the Historic Trend Line -Fairly Valued range.

14.18

P/OCF

MiMedx Group Inc. (MDXG) has a current P/OCF of 14.18. The 5-year average P/OCF is 7.86. The thresholds are as follows: Strongly Undervalued below -8.57, Undervalued between -8.57 and -0.35, Fairly Valued between 16.07 and -0.35, Overvalued between 16.07 and 24.29, and Strongly Overvalued above 24.29. The current Forward P/OCF of 14.18 falls within the Historic Trend Line -Fairly Valued range.

14.45

P/FCF

MiMedx Group Inc. (MDXG) has a current P/FCF of 14.45. The 5-year average P/FCF is 9.34. The thresholds are as follows: Strongly Undervalued below -7.34, Undervalued between -7.34 and 1.00, Fairly Valued between 17.68 and 1.00, Overvalued between 17.68 and 26.02, and Strongly Overvalued above 26.02. The current Forward P/FCF of 14.45 falls within the Historic Trend Line -Fairly Valued range.

MiMedx Group Inc (MDXG) has a current Price-to-Book (P/B) ratio of 4.90. Compared to its 3-year average P/B ratio of 45.04 , the current P/B ratio is approximately -89.11% higher. Relative to its 5-year average P/B ratio of -8.31, the current P/B ratio is about -159.02% higher. MiMedx Group Inc (MDXG) has a Forward Free Cash Flow (FCF) yield of approximately 5.38%. Compared to its 3-year average FCF yield of 1.47%, the current FCF yield is approximately 265.79% lower. Relative to its 5-year average FCF yield of -0.28% , the current FCF yield is about -2007.97% lower.

4.90

P/B

Median3y

45.04

Median5y

-8.31

5.38

FCF Yield

Median3y

1.47

Median5y

-0.28

Competitors Valuation Multiple

The average P/S ratio for MDXG's competitors is 47.23, providing a benchmark for relative valuation. MiMedx Group Inc Corp (MDXG) exhibits a P/S ratio of 2.64, which is -94.42% above the industry average. Given its robust revenue growth of 13.07%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Pulse Biosciences Inc

261.71

1.05B

IART.O

Integra Lifesciences Holdings Corp

Kestra Medical Technologies Ltd

10.69

71.40%

828.77M

Performance Decomposition

Market capitalization of MDXG increased by 4.97% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 23.81 to 34.20.

The secondary factor is the Revenue Growth, contributed 13.07%to the performance.

Overall, the performance of MDXG in the past 1 year is driven by P/E Change. Which is more unsustainable.

13.07%

87.21M → 98.61M

Revenue Growth

-51.76%

20.21 → 9.75

Margin Expansion

43.66%

23.81 → 34.20

P/E Change

4.97%